Even though a significant proportion (about 27%) of PD-L1 negative melanoma patients may benefit from anti-PD-1/PD-L1 antibodies (59), its evaluation through immunohistochemistry (IHC) from tissue sections has been historically considered one of the most valuable biomarkers capable of predicting response to immunotherapy (60). This evidence concerns the gene CD274 and melanoma.